|
US4444887A
(en)
|
1979-12-10 |
1984-04-24 |
Sloan-Kettering Institute |
Process for making human antibody producing B-lymphocytes
|
|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4716111A
(en)
|
1982-08-11 |
1987-12-29 |
Trustees Of Boston University |
Process for producing human antibodies
|
|
US4510245A
(en)
|
1982-11-18 |
1985-04-09 |
Chiron Corporation |
Adenovirus promoter system
|
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
US4968615A
(en)
|
1985-12-18 |
1990-11-06 |
Ciba-Geigy Corporation |
Deoxyribonucleic acid segment from a virus
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
ATE120454T1
(de)
|
1988-06-14 |
1995-04-15 |
Cetus Oncology Corp |
Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5413923A
(en)
|
1989-07-25 |
1995-05-09 |
Cell Genesys, Inc. |
Homologous recombination for universal donor cells and chimeric mammalian hosts
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
EP1690934A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
ATE300615T1
(de)
|
1990-08-29 |
2005-08-15 |
Genpharm Int |
Transgene mäuse fähig zur produktion heterologer antikörper
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
IE922437A1
(en)
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
ES2341666T3
(es)
|
1991-12-02 |
2010-06-24 |
Medimmune Limited |
Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US5993434A
(en)
|
1993-04-01 |
1999-11-30 |
Genetronics, Inc. |
Method of treatment using electroporation mediated delivery of drugs and genes
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
CA2219361C
(en)
|
1995-04-27 |
2012-02-28 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
|
EP1500329B1
(en)
|
1996-12-03 |
2012-03-21 |
Amgen Fremont Inc. |
Human antibodies that specifically bind human TNF alpha
|
|
US6261281B1
(en)
|
1997-04-03 |
2001-07-17 |
Electrofect As |
Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
|
|
BRPI9809391B8
(pt)
|
1997-04-14 |
2021-05-25 |
Amgen Res Munich Gmbh |
processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
|
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
US6055453A
(en)
|
1997-08-01 |
2000-04-25 |
Genetronics, Inc. |
Apparatus for addressing needle array electrodes for electroporation therapy
|
|
US6241701B1
(en)
|
1997-08-01 |
2001-06-05 |
Genetronics, Inc. |
Apparatus for electroporation mediated delivery of drugs and genes
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
US6678556B1
(en)
|
1998-07-13 |
2004-01-13 |
Genetronics, Inc. |
Electrical field therapy with reduced histopathological change in muscle
|
|
AU1728800A
(en)
|
1998-11-18 |
2000-06-05 |
Genentech Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
|
US7171264B1
(en)
|
1999-05-10 |
2007-01-30 |
Genetronics, Inc. |
Intradermal delivery of active agents by needle-free injection and electroporation
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
CA2406864A1
(en)
|
2000-02-24 |
2001-08-30 |
Life Technologies Corporation |
Simultaneous stimulation and concentration of cells
|
|
CA2401327C
(en)
|
2000-03-03 |
2014-05-06 |
Valentis, Inc. |
Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use
|
|
EP1243276A1
(en)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Elongated and multiple spacers containing activatible prodrugs
|
|
CA2443437A1
(en)
*
|
2001-05-18 |
2002-11-28 |
Boehringer Ingelheim International Gmbh |
Antibodies specific for cd44v6
|
|
EP2180044A1
(en)
|
2001-08-03 |
2010-04-28 |
GlycArt Biotechnology AG |
Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US8209006B2
(en)
|
2002-03-07 |
2012-06-26 |
Vgx Pharmaceuticals, Inc. |
Constant current electroporation device and methods of use
|
|
US20040014645A1
(en)
|
2002-05-28 |
2004-01-22 |
Advisys, Inc. |
Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
|
|
US7328064B2
(en)
|
2002-07-04 |
2008-02-05 |
Inovio As |
Electroporation device and injection apparatus
|
|
US20050070841A1
(en)
|
2002-07-04 |
2005-03-31 |
Inovio As |
Electroporation device and injection apparatus
|
|
SI1545613T1
(sl)
|
2002-07-31 |
2011-11-30 |
Seattle Genetics Inc |
Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
|
|
AU2003256038A1
(en)
|
2002-08-30 |
2004-03-19 |
Ramot At Tel Aviv University Ltd. |
Self-immolative dendrimers releasing many active moieties upon a single activating event
|
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
JP2006507322A
(ja)
|
2002-11-14 |
2006-03-02 |
シンタルガ・ビーブイ |
多重自己脱離放出スペーサーとして構築されたプロドラッグ
|
|
CN103540600B
(zh)
|
2003-01-22 |
2017-12-01 |
罗氏格黎卡特股份公司 |
融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途
|
|
AU2004213053C1
(en)
|
2003-02-20 |
2009-07-16 |
Seagen Inc. |
Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
EP1718667B1
(en)
|
2004-02-23 |
2013-01-09 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
AU2005250408B2
(en)
|
2004-05-27 |
2010-09-23 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
|
EP1810035A4
(en)
|
2004-11-10 |
2010-03-17 |
Macrogenics Inc |
GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
|
|
EP3479844B1
(en)
|
2005-04-15 |
2023-11-22 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
HUE035853T2
(en)
|
2005-07-18 |
2018-05-28 |
Seattle Genetics Inc |
Beta-glucuronide-linker-drug conjugates
|
|
US20070128708A1
(en)
|
2005-12-07 |
2007-06-07 |
Genetronics, Inc. |
Variable volume electroporation chamber and methods therefore
|
|
EP1994000B1
(en)
|
2006-02-02 |
2017-08-23 |
Syntarga B.V. |
Water-soluble cc-1065 analogs and their conjugates
|
|
WO2008070593A2
(en)
|
2006-12-01 |
2008-06-12 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
|
RS53008B2
(sr)
|
2007-04-03 |
2022-12-30 |
Amgen Res Munich Gmbh |
Interspecijski specifičan cd3-epsilon vezujući domen
|
|
EP3424951A1
(en)
|
2007-06-21 |
2019-01-09 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
EP2217283A2
(en)
|
2007-11-28 |
2010-08-18 |
Mersana Therapeutics, Inc. |
Biocompatible biodegradable fumagillin analog conjugates
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US20100152725A1
(en)
|
2008-12-12 |
2010-06-17 |
Angiodynamics, Inc. |
Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
|
|
EP2376109B1
(en)
|
2008-12-19 |
2019-01-23 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
WO2010138719A1
(en)
|
2009-05-28 |
2010-12-02 |
Mersana Therapeutics, Inc. |
Polyal drug conjugates comprising variable rate-releasing linkers
|
|
US20150165065A1
(en)
|
2009-12-31 |
2015-06-18 |
Avidbiotics Corp. |
Non-natural mic proteins
|
|
US8658765B2
(en)
|
2009-12-31 |
2014-02-25 |
Avidbiotics Corp. |
Non-natural MIC proteins
|
|
US8796420B2
(en)
|
2009-12-31 |
2014-08-05 |
Avidbiotics Corp. |
Non-natural MIC proteins
|
|
SI2531527T1
(sl)
*
|
2010-02-04 |
2014-07-31 |
F. Hoffmann-La Roche Ag |
Monoklonsko protitelo proti CD44 za uporabo pri zdravljenju skvamoznoceličnega karcinoma glave in vratu
|
|
US8349308B2
(en)
|
2010-03-26 |
2013-01-08 |
Mersana Therapeutics, Inc. |
Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
|
|
DK2560993T3
(da)
|
2010-04-20 |
2024-10-14 |
Genmab As |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
|
SG10201602394QA
(en)
|
2011-03-29 |
2016-05-30 |
Roche Glycart Ag |
Antibody FC Variants
|
|
HUE045348T2
(hu)
|
2011-05-08 |
2019-12-30 |
Legochem Biosciences Inc |
Fehérje-hatóanyag konjugátumok és eljárás elõállításukra
|
|
MY169358A
(en)
|
2011-08-23 |
2019-03-26 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
CN104244718A
(zh)
|
2011-12-05 |
2014-12-24 |
伊格尼卡生物治疗公司 |
抗体-药物缀合物以及相关化合物、组合物和方法
|
|
EP2794582A1
(en)
|
2011-12-23 |
2014-10-29 |
Mersana Therapeutics, Inc. |
Pharmaceutical formulations for fumagillin derivative-phf conjugates
|
|
MX2014010185A
(es)
|
2012-02-22 |
2014-11-14 |
Univ Pennsylvania |
Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion.
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
WO2014008375A1
(en)
|
2012-07-05 |
2014-01-09 |
Mersana Therapeutics, Inc. |
Terminally modified polymers and conjugates thereof
|
|
US10226535B2
(en)
|
2012-12-10 |
2019-03-12 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
|
CA2892863C
(en)
|
2012-12-10 |
2022-03-15 |
Mersana Therapeutics, Inc. |
Polymeric scaffold based on phf for targeted drug delivery
|
|
WO2014093640A1
(en)
|
2012-12-12 |
2014-06-19 |
Mersana Therapeutics,Inc. |
Hydroxy-polmer-drug-protein conjugates
|
|
EP2935608A1
(en)
|
2013-10-14 |
2015-10-28 |
SynAffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
EP3058083B1
(en)
|
2013-10-14 |
2018-04-11 |
SynAffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
WO2015057066A1
(en)
|
2013-10-14 |
2015-04-23 |
Synaffix B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
|
EP3057618B1
(en)
|
2013-10-14 |
2022-12-14 |
SynAffix B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
|
WO2015112013A1
(en)
|
2014-01-24 |
2015-07-30 |
Synaffix B.V. |
Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained thereby
|
|
KR101628872B1
(ko)
|
2014-05-28 |
2016-06-09 |
주식회사 레고켐 바이오사이언스 |
자가-희생 기를 포함하는 화합물
|
|
JP6464255B2
(ja)
|
2014-08-04 |
2019-02-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性ｔ細胞活性化抗原結合分子
|
|
EP3177633B1
(en)
|
2014-08-04 |
2022-07-20 |
SynAffix B.V. |
Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
|
|
WO2016053107A1
(en)
|
2014-10-03 |
2016-04-07 |
Synaffix B.V. |
Sulfamide linker, conjugates thereof, and methods of preparation
|
|
US11117969B2
(en)
|
2014-12-05 |
2021-09-14 |
Xyphos Biosciences Inc. |
Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands
|
|
EP4043474A1
(en)
|
2014-12-05 |
2022-08-17 |
Xyphos Biosciences Inc. |
Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
|
|
CN107810273B
(zh)
|
2015-04-23 |
2022-09-27 |
西纳福克斯股份有限公司 |
用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法
|
|
BR112017023943A2
(pt)
|
2015-05-08 |
2018-07-31 |
Xencor, Inc. |
anticorpos heterodimêricos que ligam cd3 e antígenos de tumor
|
|
CN107995913B
(zh)
|
2015-05-18 |
2022-02-11 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
|
CN105169402B
(zh)
*
|
2015-05-28 |
2018-03-16 |
中山大学孙逸仙纪念医院 |
靶向免疫治疗胰腺癌的载药纳米微粒及其应用
|
|
HRP20240997T1
(hr)
|
2015-08-04 |
2024-10-25 |
Xyphos Biosciences Inc. |
Varijabilni fragmenti antitijela koji se mogu umetnuti i modificirane α1-α2 domene nkg2d liganada, kao i neprirodni nkg2d ligandi koji se vežu za neprirodne nkg2d receptore
|
|
WO2017051249A1
(en)
|
2015-09-25 |
2017-03-30 |
Legochem Biosciences, Inc. |
Compositions and methods related to anti-cd19 antibody drug conjugates
|
|
WO2017051254A1
(en)
|
2015-09-25 |
2017-03-30 |
Legochem Biosciences, Inc. |
Compositions and methods related to anti-egfr antibody drug conjugates
|
|
EP3842450A1
(en)
|
2015-10-23 |
2021-06-30 |
Eureka Therapeutics, Inc. |
Antibody/t-cell receptor chimeric constructs and uses thereof
|
|
HRP20240795T1
(hr)
|
2015-11-25 |
2024-09-13 |
Ligachem Biosciences Inc. |
Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
|
|
AU2016359234B2
(en)
|
2015-11-25 |
2022-09-08 |
Ligachem Biosciences Inc. |
Conjugates comprising peptide groups and methods related thereto
|
|
KR102847350B1
(ko)
|
2015-11-25 |
2025-08-19 |
주식회사 리가켐바이오사이언스 |
분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법
|
|
CN109152844B
(zh)
|
2016-02-08 |
2022-11-22 |
西纳福克斯股份有限公司 |
用于治疗的含有磺酰胺接头的生物缀合物
|
|
WO2017137423A1
(en)
|
2016-02-08 |
2017-08-17 |
Synaffix B.V. |
Improved sulfamide linkers for use in bioconjugates
|
|
WO2017137457A1
(en)
|
2016-02-08 |
2017-08-17 |
Synaffix B.V. |
Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
|
|
AU2016410294A1
(en)
|
2016-06-24 |
2019-01-03 |
Xyphos Biosciences Inc. |
Insertable variable fragments of antibodies and modified a1-a2 domains of NKG2D ligands
|
|
EP3494138A1
(en)
|
2016-08-02 |
2019-06-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US11446388B2
(en)
|
2016-12-23 |
2022-09-20 |
Heidelberg Pharma Research Gmbh |
Amanitin antibody conjugates
|
|
WO2018182341A1
(ko)
|
2017-03-29 |
2018-10-04 |
주식회사 레고켐 바이오사이언스 |
피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
|
|
CN107441505A
(zh)
*
|
2017-09-11 |
2017-12-08 |
东南大学 |
一种靶向磁性纳米脂质体及其制备方法
|
|
MX2020010003A
(es)
|
2018-03-27 |
2021-01-15 |
Xyphos Biosciences Inc |
Dominios a1-a2 modificados de ligandos nkg2d no naturales que se unen a receptores nkg2d no naturales.
|
|
JP2021521202A
(ja)
|
2018-04-13 |
2021-08-26 |
ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
固形腫瘍の治療のための標的化されたアマトキシン複合体
|
|
WO2019222275A2
(en)
|
2018-05-14 |
2019-11-21 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using inducible fusion proteins
|
|
CN110818802B
(zh)
|
2018-08-08 |
2022-02-08 |
华夏英泰（北京）生物技术有限公司 |
一种嵌合t细胞受体star及其应用
|
|
WO2020141923A2
(ko)
|
2019-01-03 |
2020-07-09 |
주식회사 레고켐 바이오사이언스 |
안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
|
|
AU2020233286B2
(en)
|
2019-03-01 |
2022-10-20 |
Mercy Bioanalytics, Inc. |
Systems, compositions, and methods for target entity detection
|
|
JP2022530482A
(ja)
|
2019-05-02 |
2022-06-29 |
レゴケム バイオサイエンシズ， インク． |
トリス構造を有するリンカーを含むリガンド―薬物複合体
|
|
US20200370013A1
(en)
|
2019-05-20 |
2020-11-26 |
The Trustees Of The University Of Pennsylvania |
Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors
|
|
WO2021137646A1
(ko)
|
2019-12-31 |
2021-07-08 |
주식회사 레고켐바이오사이언스 |
피롤로벤조디아제핀 유도체 및 이의 리간드-링커 접합체
|
|
EP4114860A1
(en)
*
|
2020-03-06 |
2023-01-11 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|